Curacle Selected as Bio-Europe Spring Presentation Company

[Asia Economy Reporter Hyungsoo Park] Curacle announced on the 14th that it has been selected as a presentation company for 'Bio-Europe Spring 2022,' which will be held from the 28th to the 31st (local time).

'Bio-Europe Spring' is the largest bio conference in Europe attended by pharmaceutical and bio companies and investors from around the world. This year, about 100 companies worldwide were selected as corporate presentation companies. Among them, seven companies from Korea were included, including Curacle, a specialized company in developing new drugs for vascular and intractable diseases related to aging.

During the conference, Curacle will hold partnership meetings with major overseas pharmaceutical companies and investors. It will introduce its mid- to long-term strategies and key pipelines. The opportunity will be used to showcase its excellent technology, current clinical development status, future clinical development strategies, and vision.

An official stated, "Starting with participation in the JP Morgan Healthcare Conference in January, we will share our excellent technology and business strategies through the Bio-Europe Spring conference," adding, "We will do our best to achieve meaningful results."

Curacle will also introduce six new projects discovered through the SOLVADYS® platform technology, specialized in developing vascular endothelial dysfunction blockers, along with the CU06 pipeline currently undergoing clinical research. The projects to be actively developed from this year include CU101 (myocardial infarction), CU102 (acute lung injury), CU103 (stroke), CU104 (ulcerative colitis), CU105 (hereditary/allergic angioedema), and CU106 (immune-oncology combination therapy).

Curacle is a company developing treatments for various intractable diseases by blocking vascular endothelial dysfunction with a new mechanism of action. In October last year, it licensed out (L/O) the candidate substance 'CU06' for diabetic macular edema and wet age-related macular degeneration to the French company Thea Open Innovation. Going forward, Curacle plans to continue its growth trend by securing additional milestones (stage-based royalties) and expanding indications for the candidate substance.

This content was produced with the assistance of AI translation services.